rhG-CSF对供者骨髓和外周血采集物中Th17细胞的影响

本研究探讨人重组粒细胞集落刺激因子（rhG-CSF）供者体内应用对骨髓采集物（GBM）和外周血采集物（GPB）中Th17细胞的影响。对25名亲缘供者皮下注射rhG-CSF5μg/（kg.d）,连用5天,于第4、5天分别采集骨髓和外周血,注射前留取部分供者稳态骨髓（steady state bone mavrow,SSBM）和稳态外周血（steady state peripheral blood,SSPB）。采用流式细胞术测定动员前后供者骨髓和外周血中T细胞分泌IL-17的变化。结果显示：rhG-CSF体内应用后供者骨髓中CD4＋T细胞和CD8＋T细胞分泌Il-17的能力较稳态骨髓明显下降（GBM vs SSBM Th17/CD4＋T,0.74%±0.27%vs1.78%±1.19%,p〈0.05;Tc17/CD8＋T,0.19%±0.16% vs 0.36%±0.37%,p〈0.05）,外周血中的变化与骨髓相同（GPBvsSSPBTh17/CD4＋ T,1.82%±0.91%vs3.26%±1.89%,p〈0.01;Tc17/CD8＋T,0.21%±0.17%vs0.44%±0.28%,p〈0.01）。25例供者GBM与GPB相比,GPB中Th17/CD4＋ T和Tc17/CD8＋ T的比值均高于GBM（p〈0.05,p〈0.01）。结论：体内应用rhG-CSF能够抑制供者骨髓及外周血采集物中Th17细胞的产生,它可能是GPB和/或GBM混合移植对GVHD的发生率没有增加的部分原因。

Effects of rhG-CSF Mobilization on Th17 Cells in Donors' Peripheral Blood and Bone Marrow Grafts

The study was aimed to explore the effects of recombination human granulocyte colony-stimulating factor （rhG-CSF） on Th17 cells in donors′ peripheral blood （GPB） and bone marrow grafts （GBM）. 25 healthy donors were injected subcutaneously with rhG-CSF 5 μg/（kg·d） for 5 consecutive days. GBM and GPB were harvested after injection on day 4 and 5 respectively. Some of these donors′ steady-state bone marrow （SSBM） and steady-state peripheral blood （SSPB） were harvested before rhG-CSF injection. The changes of IL-17 secreted by T cells in donor BM and PB before and after mobilization were detected by flow cytomefry. The results showed that the ability to secrete IL-17 from CD4＋ T cells and CD8＋ T cells in GBM was significantly lower than those in SSBM（GBM vs SSBM Th17/ CD4＋ T,0.74%±0.27% vs 1.78%± 1.19%, p 0.05;Tc17/CD8＋T, 0.19%±0.16% vs 0.36%±0.37%, p0.05）,changes in peripheral blood and bone marrow were same （GPB vs SSPB Th17/CD4＋ T, 1.82%±0.91% vs 3.26%± 1.89%, p0.01; Tc17/CD8＋ T, 0.21% ± 0.17% vs 0.44% ± 0.28%, p0.01）. The ratios of Th17 /CD4＋ T and Tc17/CD8＋ T in GPB were higher than in GBM （p 0.05, p0.01）. It is concluded that rhG-CSF in vivo can inhibit the generation of Th17 cells both in bone marrow and peripheral blood grafts, and it may be partial reason for GPB/GBM mixed transplantation without increasing the GVHD incidence.